European CURE-AF Study
European CURE-AF Study - Concomitant Utilization of Radiofrequency Energy for Atrial Fibrillation
調査の概要
詳細な説明
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
Beneke Str. 2-8
-
Bad Nauheim、Beneke Str. 2-8、ドイツ、61231
- Kerckhoff Clinic - Department of Thoracic & Cardiovascular Surgery
-
-
Leipziger Strasse 50
-
Cottbus、Leipziger Strasse 50、ドイツ、03048
- Heart Center Cottbus - Department of Cardiac Surgery
-
-
-
-
Hans Nissens Gate 3
-
Trondheim、Hans Nissens Gate 3、ノルウェー、7018
- St. Elizabeth Heart Center - Department of Cardiothoracic Surgery
-
-
Jonas Liesvei 65
-
Bergen、Jonas Liesvei 65、ノルウェー、5021
- Haukeland University Hospital - Department of Cardiothoracic Surgery
-
-
-
-
Ul. Banacha 1a
-
Warsaw、Ul. Banacha 1a、ポーランド、02-097
- Public Central Teaching Hospital - Department of Cardiac Surgery
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
Patients must meet all of the following criteria to be enrolled in the study:
- Documented history of AF a For inclusion in permanent AF arm: Patients must have a documented history of permanent AF (cardioversion failure) as defined by the ACC/AHA/ESC Guidelines; Documentation of AF must include one or more chart references to AF and/or one or more ECG's with AF prior to the patient's surgery. Other supporting information could include references to cardioversion attempts using either drugs or electrical shock. b For inclusion in persistent AF arm: Patients must have a documented history of persistent AF as defined by the ACC/AHA/ESC Guidelines: characterized as episodes of non-self-terminating atrial fibrillation that usually lasts more than 7 days
- Concomitant indication (other than AF) for open-heart surgery for one or more of the following:
a Mitral valve repair or replacement, b Aortic valve repair or replacement, c Tricuspid valve repair or replacement, d ASD repair, e PFO closure, or f CABG procedures; 3 Able to take the anticoagulant warfarin or other ACC/AHA/ESC-recommended anticoagulant medication; 4 Greater than or equal to 18 years of age; 5 Able and willing to comply with study requirements by signing a Patient Informed Consent form.
Exclusion Criteria:
Patients who meet any of the following criteria may not be enrolled in the study:
1 Wolff-Parkinson-White syndrome, 2 NYHA functional class = IV, 3 Left ventricular ejection fraction ≤ 30%, 4 Left atrial diameter > 7.0 cm, 5. Need for emergent cardiac surgery (i.e. cardiogenic shock) or redo open heart surgery, 6 Preoperative need for an intra-aortic balloon pump or intravenous inotropes, 7 Previous atrial ablation, AV-nodal ablation, or surgical Maze procedure, 8 Contraindication for anticoagulation therapy, 9 Current diagnosis of active systemic infection, 10 Renal failure requiring dialysis or hepatic failure, 11 Documented myocardial infarction 6 weeks prior to study enrollment, 12 Life expectancy of less than one year, or 13 Pregnancy or desire to be pregnant within 12-months of the study treatment.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:CURE AF
|
この調査は、心房細動を伴う患者の転帰を評価する前向き非無作為化多施設臨床試験であり、付随する開胸手術と、修正されたメイズ III 手順を使用した心臓切除手術システムが必要です。
試験集団には、弁の置換または修復、心房中隔欠損症 (ASD) 修復、卵円孔開存 (PFO) 閉鎖、または冠動脈バイパス移植 (CABG) 処置を必要とする患者が含まれます。
This investigation is a prospective, non-randomized multicenter clinical trial evaluating the outcome of patients with AF requiring concomitant open heart surgery plus the Cardioblate Surgical Ablation System using the modified Maze III procedure.
The trial population includes patients requiring valve replacements or repairs, atrial septal defect (ASD) repairs, patent foramen ovale (PFO) closure or coronary artery bypass grafts (CABG) procedures.
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Permanent AF Arm
時間枠:24-hour Holter recording at 6 months follow-up
|
Primary efficacy endpoint- The percent of patients free of AF, off Class I or III antiarrhythmic drugs and not having received additional ablation therapy, as determined by a 24-hour Holter recording at 6 months follow-up.
|
24-hour Holter recording at 6 months follow-up
|
|
Persistent AF Arm
時間枠:24-hour Holter recording at 9 months follow-up.
|
The percent of patients free of AF, off Class I or III antiarrhythmic drugs and not having received additional ablation therapy, as determined by a 24-hour Holter recording at 9 months follow-up.
|
24-hour Holter recording at 9 months follow-up.
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Permanent AF Arm
時間枠:24 hours
|
Secondary efficacy endpoints - 24-hour Holter recording, b) improvement in left ventricular ejection fraction and c) left atrial transport function as evidenced by the presence of an A wave at 6 months follow-up.
|
24 hours
|
|
Persistent AF Arm
時間枠:24-hour Holter recording at 9 months follow-up.
|
Secondary efficacy endpoints - a) The percent of patients free of AF, regardless of Class I or III antiarrhythmic drug use and not having received additional ablation therapy, as determined by a 24-hour Holter recording, b) improvement in left ventricular ejection fraction and c) left atrial transport function as evidenced by the presence of an A wave at 9 months follow-up.
|
24-hour Holter recording at 9 months follow-up.
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。